Your browser is no longer supported. Please, upgrade your browser.
Settings
CDMOP Avid Bioservices, Inc. daily Stock Chart
CDMOP [NASD]
Avid Bioservices, Inc.
Index- P/E- EPS (ttm)-0.56 Insider Own7.06% Shs Outstand44.01M Perf Week1.70%
Market Cap1.15B Forward P/E- EPS next Y- Insider Trans- Shs Float44.01M Perf Month0.91%
Income- PEG- EPS next Q- Inst Own0.72% Short Float0.02% Perf Quarter4.59%
Sales53.62M P/S21.39 EPS this Y- Inst Trans- Short Ratio3.73 Perf Half Y4.38%
Book/sh1.00 P/B26.04 EPS next Y- ROA- Target Price- Perf Year18.47%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range21.24 - 27.00 Perf YTD6.82%
Dividend2.62 P/FCF- EPS past 5Y- ROI- 52W High-3.47% Beta-
Dividend %10.05% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low22.71% ATR0.31
Employees185 Current Ratio- Sales Q/Q-61.20% Oper. Margin- RSI (14)55.98 Volatility1.25% 0.99%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.52 Prev Close26.06
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume2.18K Price26.06
Recom- SMA200.95% SMA501.44% SMA2005.04% Volume3,316 Change0.03%
Aug-08-18 08:05AM  Avid Bioservices to Exhibit at the Bioprocessing Summit 2018 GlobeNewswire
Jul-17-18 08:05AM  Avid Bioservices Announces Appointment of Daniel Hart as Chief Financial Officer GlobeNewswire
Jul-16-18 04:05PM  Avid Bioservices Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2018 and Recent Developments GlobeNewswire
02:30PM  Avid Bioservices, Inc. to Host Earnings Call ACCESSWIRE
Jul-09-18 08:05AM  Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2018 After Market Close on July 16, 2018 GlobeNewswire
Jun-25-18 08:05AM  Avid Bioservices Added to Russell 3000® Index and Russell 2000® Index GlobeNewswire
Jun-06-18 04:05PM  Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock GlobeNewswire
May-29-18 08:05AM  Avid Bioservices to Participate at BIO International Convention 2018 GlobeNewswire
May-08-18 08:05AM  Avid Bioservices Announces Appointment of Magnus Schroeder, Ph.D., as Vice President of Process Sciences GlobeNewswire
Apr-24-18 08:05AM  Avid Bioservices Provides Update on Ongoing Expansion of Process Development Capabilities and Laboratory Infrastructure GlobeNewswire
Apr-09-18 08:05AM  Avid Bioservices to Participate at INTERPHEX 2018 GlobeNewswire
Mar-22-18 08:05AM  Avid Bioservices Receives Six 2018 CMO Leadership Awards GlobeNewswire
Mar-13-18 08:05AM  Avid Bioservices to Participate at Upcoming CDMO Industry Conferences GlobeNewswire
Mar-12-18 04:05PM  Avid Bioservices Reports Financial Results for Third Quarter of Fiscal Year 2018 and Recent Developments GlobeNewswire
Mar-07-18 04:05PM  Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock GlobeNewswire
Mar-06-18 08:05AM  Avid Bioservices to Present at the 30th Annual ROTH Conference GlobeNewswire
Mar-05-18 08:05AM  Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2018 After Market Close on March 12, 2018 GlobeNewswire
Mar-01-18 08:05AM  Avid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture of Novel Alzheimers Disease Candidate GlobeNewswire
Feb-26-18 08:05AM  Avid Bioservices Announces Resignation of Chief Financial Officer GlobeNewswire
Feb-21-18 08:05AM  Avid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by Enzyvant, a Subsidiary of Roivant Sciences GlobeNewswire
Feb-20-18 04:05PM  Avid Bioservices Announces Closing of Public Offering of Common Stock GlobeNewswire
Avid Bioservices, Inc., a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission, and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.